The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial

被引：0

作者：

Walensky, R. P. ^{[1
,2
,6
]}

Ross, E. L. ^{[1
]}

Kumarasamy, N. ^{[7
]}

Wood, R. ^{[8
,9
]}

Noubary, F. ^{[1
]}

Paltiel, A. D. ^{[10
]}

Nakamura, Y. M. ^{[1
]}

Godbole, S. ^{[11
]}

Hosseinipour, M. ^{[12
,13
]}

Hakim, J. G. ^{[14
]}

Kumwenda, J. ^{[15
]}

Makhema, J. ^{[5
]}

Akelo, V. ^{[16
]}

Panchia, R. ^{[17
]}

Sanne, I. ^{[18
]}

Weinstein, M. C. ^{[4
]}

Losina, E. ^{[3
,6
,19
]}

Mayer, K. H. ^{[20
]}

Grinsztejn, B. ^{[21
]}

Pilotto, J. ^{[22
,23
]}

Chariyalertsak, S. ^{[24
]}

Santos, B. ^{[25
]}

Chen, Y. Q. ^{[26
]}

Wang, L. ^{[26
]}

Li, X. ^{[26
]}

McCauley, M. ^{[27
]}

Gamble, T. ^{[28
]}

Piwowar-Manning, E. ^{[29
]}

Cottle, L. ^{[30
]}

Hoffman, I. ^{[31
]}

Eron, J. ^{[31
]}

Gallant, J. ^{[29
]}

Swindells, S. ^{[32
]}

Taha, T. ^{[33
]}

Nielsen-Saines, K. ^{[34
]}

Celentano, D. ^{[33
]}

Essex, M. ^{[4
]}

Elharrar, V. ^{[35
]}

Burns, D. ^{[35
]}

Seage, G. R. ^{[4
]}

Cohen, M. S. ^{[31
]}

Freedberg, K. A. ^{[1
,2
,19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Harvard Ctr AIDS Res, Boston, MA USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Botswana Harvard AIDS Inst, Gaborone, Botswana

[6] Brigham & Womens Hosp, Boston, MA 02115 USA

[7] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India

[8] Univ Cape Town, ZA-7925 Cape Town, South Africa

[9] Desmond Tutu HIV Ctr, Cape Town, South Africa

[10] Yale Univ, Sch Med, New Haven, CT USA

[11] NARI, Pune, Maharashtra, India

[12] Univ N Carolina Chapel Hill, Lilongwe, Malawi

[13] UNC Project Malawi, Lilongwe, Malawi

[14] Univ Zimbabwe, Dept Med, Harare, Zimbabwe

[15] Coll Med Johns Hopkins Project, Blantyre, Malawi

[16] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya

[17] Univ Witwatersrand, PHRU, Johannesburg, South Africa

[18] Univ Witwatersrand, Dept Med, Johannesburg, South Africa

[19] Boston Univ, Sch Publ Hlth, Boston, MA USA

[20] Fenway Inst, Boston, MA USA

[21] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil

[22] Fiocruz MS, Hosp Geral Nova Iguacu, BR-21045900 Rio De Janeiro, Brazil

[23] Fiocruz MS, Lab AIDS & Imunol Mol IOC, BR-21045900 Rio De Janeiro, Brazil

[24] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand

[25] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil

[26] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA

[27] FHI 360, Washington, DC USA

[28] FHI 360, Durham, NC USA

[29] Johns Hopkins Sch Med, Baltimore, MD USA

[30] SCHARP, Seattle, WA USA

[31] Univ N Carolina, Sch Med, Chapel Hill, NC USA

[32] Univ Nebraska Med Ctr, Omaha, NE USA

[33] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA

[34] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA

[35] NIAID, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：116 / 117

页数：2

共 50 条

[21] Avahan and the cost-effectiveness of "prevention as prevention"
Marseille, Elliot
Kahn, James G.
LANCET GLOBAL HEALTH, 2014, 2 (09): : E493 - E494
[22] Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
Hiligsmann, Mickael
Vanoverberghe, Marie
Neuprez, Audrey
Bruyere, Olivier
Reginster, Jean-Yves
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (04) : 359 - 366
[23] Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Hontelez, Jan A. C.
de Vlas, Sake J.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (06): : 581 - 581
[24] Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis
Zethraeus, N
Ben Sedrine, W
Caulin, F
Corcaud, S
Gathon, HJ
Haim, M
Johnell, O
Jönsson, B
Kanis, JA
Tsouderos, Y
Reginster, JY
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (11) : 841 - 857
[25] Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis
N. Zethraeus
W. Ben Sedrine
F. Caulin
S. Corcaud
H. J. Gathon
M. Haim
O. Johnell
B. Jönsson
J. A. Kanis
Y. Tsouderos
J.-Y. Reginster
Osteoporosis International, 2002, 13 : 841 - 857
[26] Cost-Effectiveness of Caries Prevention in Practice: A Randomized Controlled Trial
O'Neill, C.
Worthington, H. V.
Donaldson, M.
Birch, S.
Noble, S.
Killough, S.
Murphy, L.
Greer, M.
Brodison, J.
Verghis, R.
Tickle, M.
JOURNAL OF DENTAL RESEARCH, 2017, 96 (08) : 875 - 880
[27] Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
Stevanovic, J.
de Jong, L. A.
Kappelhoff, B. S.
Dvortsin, E. P.
Voorhaar, M.
Postma, M. J.
PLOS ONE, 2016, 11 (10):
[28] Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands
de Jong, Lisa A.
Dvortsin, Evgeni
Janssen, Kristel J.
Postma, Maarten J.
CLINICAL THERAPEUTICS, 2017, 39 (02) : 288 - 302
[29] COST-EFFECTIVENESS ANALYSIS FOR APIXABAN IN THE ACUTE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM IN THE NETHERLANDS
De Jong, L.
Dvortsin, E. P.
Janssen, K. J.
Postma, M. J.
VALUE IN HEALTH, 2016, 19 (07) : A651 - A651
[30] Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
Heisen, Marieke
Treur, Maarten J.
Heemstra, Harald E.
Giesen, Eric B. W.
Postma, Maarten J.
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 813 - 824

← 1 2 3 4 5 →